MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2010-04-26
Last Posted Date
2010-04-27
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
49
Registration Number
NCT01110317

Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2010-04-20
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
74
Registration Number
NCT01106469

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2010-04-16
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
32
Registration Number
NCT01105780

Ketamine Challenge Study With JNJ-40411813

Phase 1
Completed
Conditions
Perceptual Disorders
Confusion
Schizophrenia
Interventions
Drug: Placebo
Drug: normal saline
First Posted Date
2010-04-12
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
40
Registration Number
NCT01101659

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Gastroesophageal Reflux
Interventions
First Posted Date
2010-04-12
Last Posted Date
2014-05-28
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
36
Registration Number
NCT01101646

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Phase 1
Completed
Conditions
Schizophrenia
Bipolar Disorder
Psychotic Disorders
Interventions
Drug: divalproex sodium ER/paliperidone ER
First Posted Date
2010-03-26
Last Posted Date
2014-04-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
9
Registration Number
NCT01094249

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Phase 2
Terminated
Conditions
Pain
Osteoarthritis
Osteoarthritis, Knee
Arthralgia
Joint Pain
Interventions
First Posted Date
2010-03-26
Last Posted Date
2020-03-11
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
196
Registration Number
NCT01094262

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: single dose NJ-39758979/ matching placebo
Drug: multi-dose JNJ-39758979 /matching placebo
First Posted Date
2010-03-05
Last Posted Date
2013-09-06
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
61
Registration Number
NCT01081821

A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers

Phase 1
Completed
Conditions
Histamine Induced Itch
First Posted Date
2010-02-12
Last Posted Date
2013-09-04
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
24
Registration Number
NCT01068223
© Copyright 2025. All Rights Reserved by MedPath